We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 721

Post exclusivity issues for biologics

  • Andrews Kurth LLP
  • -
  • USA
  • -
  • December 22 2014

Investments in research resulting in new drug inventions have long taken advantage of patent protection, but such investments may also benefit from

“Pretext” or not? pharma waits for the Second Circuit’s decision in Actavis

  • Fish & Richardson PC
  • -
  • USA
  • -
  • December 17 2014

On December 15, Judge Robert Sweet of the Southern District of New York issued an injunction against Actavis, forcing Actavis to continue selling its

Preliminary injunction order in Actavis casts a skeptical eye toward the “hard switch”

  • Patterson Belknap Webb & Tyler LLP
  • -
  • USA
  • -
  • December 17 2014

Last week, we briefly reported on the injunction granted by the U.S. District Court for the Southern District of New York in the New York Attorney

Lessons learned from first Final Written Decision in a Hatch-Waxman related inter partes review

  • Paul Hastings LLP
  • -
  • USA
  • -
  • December 16 2014

Last week, the Patent Trial and Appeal Board issued Final Written Decisions in three inter partes review proceedings upholding the patentability of

The Beat Goes On: antitrust enforcement and healthcare

  • Baker & Hostetler LLP
  • -
  • USA
  • -
  • December 12 2014

In one form or another, the Federal Trade Commission (FTC) has been banging the drum that there is no inconsistency between antitrust enforcement and

Preliminary injunction precludes Actavis from pulling current version of Namenda off the market

  • Patterson Belknap Webb & Tyler LLP
  • -
  • USA
  • -
  • December 12 2014

Yesterday, Judge Robert Sweet granted the New York Attorney General's request to block Actavis and its New York-based subsidiary Forest Laboratories

Jury finds for drug manufacturers in first post-Actavis "reverse payment" trial

  • Jones Day
  • -
  • USA
  • -
  • December 11 2014

In the first "reverse payment" trial since the U.S. Supreme Court’s Actavis decision held that "reverse payment" settlements potentially could be

Made in Canada approach to pay for delay: bureau at odds with US approach

  • Cassels Brock & Blackwell LLP
  • -
  • USA
  • -
  • December 8 2014

Last week, a US Federal Court ruled that AstraZeneca Plc's payment to Ranbaxy Laboratories Ltd. to delay a generic version of heartburn medication

Court allows “product hopping” claims to proceed in Suboxone litigation based on allegations of removal of prior formulation and disparagement of generic competition

  • Patterson Belknap Webb & Tyler LLP
  • -
  • USA
  • -
  • December 8 2014

We've previously discussed antitrust claims related to "product hopping"allegations that pharmaceutical manufacturers have reformulated or

FDA citizen petition may give rise to antitrust liability; factual issues exist concerning whether ANDA infringement claim was objectively baseless

  • Fish & Richardson PC
  • -
  • USA
  • -
  • December 6 2014

Federal Circuit reverses summary judgment of no sham litigation related to an infringement suit and FDA citizen’s petition but affirms summary